Prestige Consumer Healthcare (NYSE:PBH) Announces Earnings Results, Misses Expectations By $0.16 EPS

Prestige Consumer Healthcare (NYSE:PBH) released its quarterly earnings results on Wednesday. The company reported $1.23 EPS for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16), FiscalAI reports. The company had revenue of $281.62 million during the quarter, compared to analysts’ expectations of $291.99 million. Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.62%. The company’s quarterly revenue was down 5.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.32 earnings per share. Prestige Consumer Healthcare updated its FY 2027 guidance to 4.420-4.510 EPS.

Prestige Consumer Healthcare Stock Performance

Shares of Prestige Consumer Healthcare stock traded up $0.76 during trading hours on Friday, hitting $46.69. 1,727,245 shares of the company’s stock traded hands, compared to its average volume of 508,464. Prestige Consumer Healthcare has a 12-month low of $42.62 and a 12-month high of $89.37. The stock has a market capitalization of $2.21 billion, a price-to-earnings ratio of 11.94, a PEG ratio of 1.55 and a beta of 0.40. The company has a fifty day simple moving average of $58.32 and a 200-day simple moving average of $61.49. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.11 and a quick ratio of 1.93.

Insider Activity

In other news, VP Jeffrey Zerillo sold 1,207 shares of the firm’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total transaction of $66,372.93. Following the completion of the sale, the vice president directly owned 42,820 shares of the company’s stock, valued at $2,354,671.80. This trade represents a 2.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 1.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Several large investors have recently made changes to their positions in PBH. Squarepoint Ops LLC increased its position in shares of Prestige Consumer Healthcare by 316.1% during the 3rd quarter. Squarepoint Ops LLC now owns 301,866 shares of the company’s stock valued at $18,836,000 after purchasing an additional 229,311 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Prestige Consumer Healthcare by 28.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock worth $46,997,000 after acquiring an additional 120,965 shares during the period. Bank of America Corp DE grew its stake in shares of Prestige Consumer Healthcare by 19.1% during the 2nd quarter. Bank of America Corp DE now owns 721,371 shares of the company’s stock worth $57,601,000 after acquiring an additional 115,459 shares during the period. Man Group plc bought a new position in shares of Prestige Consumer Healthcare during the 3rd quarter worth $6,808,000. Finally, Raymond James Financial Inc. grew its stake in shares of Prestige Consumer Healthcare by 15.7% during the 3rd quarter. Raymond James Financial Inc. now owns 637,932 shares of the company’s stock worth $39,807,000 after acquiring an additional 86,373 shares during the period. 99.95% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on PBH. Oppenheimer lowered Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday. Jefferies Financial Group lowered their price target on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research report on Friday, January 30th. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Tuesday, April 21st. Finally, Canaccord Genuity Group lowered their price target on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research report on Friday. Two equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $70.75.

Prestige Consumer Healthcare News Roundup

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Prestige Consumer Healthcare said it is acquiring LaCorium Health, a deal that could expand its portfolio and support future growth. Prestige Consumer Healthcare Inc. Reports Fiscal 2026 Results, Announces Acquisition of LaCorium Health
• Positive Sentiment: Canaccord Genuity kept a buy rating on PBH even after cutting its price target to $72 from $86, indicating analysts still see meaningful upside from current levels. Benzinga report on Canaccord Genuity price target cut
• Neutral Sentiment: Investors are also digesting the Q4 2026 earnings call and transcript, which may provide more detail on management’s growth plan and margin outlook. Prestige (PBH) Q4 2026 Earnings Transcript
• Neutral Sentiment: Oppenheimer downgraded Prestige Consumer Healthcare, adding to the mixed analyst reaction following the earnings release and likely contributing to volatility in the stock. Oppenheimer downgrades Prestige Consumer Healthcare (PBH)
• Negative Sentiment: Levi & Korsinsky said it has launched an investigation into possible securities law violations, after comments on the earnings call raised questions about expected Q4 adjusted gross margin, which could create legal and headline risk for PBH. Newsfile investigation article
• Negative Sentiment: The core earnings report was disappointing: PBH missed EPS and revenue estimates, revenue fell 5% year over year, and the company issued FY2027 guidance below consensus, reinforcing concerns about slowing growth and pressure on margins. Prestige Consumer Healthcare fiscal 2026 results and acquisition release

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).